DNA encoding human papillomavirus type 18

• US 5,840,306 A
• Filed: 03/22/1995
• Issued: 11/24/1998
• Est. Priority Date: 03/22/1995
• Status: Expired due to Term

• Current Assignee: Merck Sharp & Dohme Corporation (Merck & Co., Inc.)
• Original Assignee: Merck & Co., Inc.
• Inventors: Neeper, Michael P., Jansen, Kathrin U., Hofmann, Kathryn J.
• Primary Examiner(s): Guzo, David
• Application Number:
  US08/408,669
• Time in Patent Office: 1,343 Days
• Field of Search: 435/69.1, 435/172.1, 435/172.3, 435/320.1, 435/69.3, 435/348, 435/365, 435/254.21, 536/23.1, 536/23.72, 424/204.1, 424/93.1, 424/93.2, 424/93.6, 424/186.1, 514/44
• US Class Current: 424/192.1
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: Y10S 977/803 Containing biological material in its interior
• CPC Class Codes: Y10S 977/915 Therapeutic or pharmaceutical composition
• CPC Class Codes: Y10S 977/918 Immunological
• CPC Class Codes: Y10S 977/924 using nanostructure as support of dna analysis

Abstract

The present invention is directed to DNA molecules encoding purified human papillomavirus type 18 and derivatives thereof.

Claims

1. An isolated nucleic acid encoding the amino acid sequence of FIG. 1 (SEQ ID NO:

2).

2. The nucleic acid according to claim 1 which is a DNA.

3. The DNA according to claim 2 which is shown in FIG. 1 (SEQ ID NO:

1).

4. A vector comprising a nucleic acid encoding the amino acid sequence of FIG. 1 (SEQ ID NO:

2).

5. A cell comprising the vector of claim 4.

6. An isolated nucleic acid encoding the amino acid sequence of FIG. 3 (SEQ ID NO:

4).

7. The nucleic acid according to claim 6 which is a DNA.

8. The DNA according to claim 7 which is shown in FIG. 3 (SEQ ID NO:

3).

9. A vector comprising a nucleic acid encoding the amino acid sequence of FIG. 3 (SEQ ID NO:

4).

10. A cell comprising the vector of claim 9.

11. A process for expressing human papilloma virus type 18 protein in a host comprising:

(a) transforming a host cell with a vector comprising a nucleic acid encoding the amino acid sequence of SEQ ID NO;

2 or SEQ ID NO;

4;

(b) culturing the host cell under conditions which allow expression of the protein from the vector.

12. A composition which induces an immune response in a subject treated with die composition, the composition comprising a nucleic acid encoding the amino acid sequence of SEQ ID NO:

2 or SEQ ID NO;

4 in a pharmaceutically acceptable carrier.

13. A method of inducing an immune response against an infection or disease caused by human papillomavirus 18 which comprises introducing into a susceptible animal a composition of claim 12.